These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 3802423)

  • 1. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
    Toth PD; Mikulaschek AW
    Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
    Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
    J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the platelet activating factor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride on endotoxin-induced hypotension and hematological parameters in rats.
    Natsume Y; Imanishi N; Koike H; Morooka S
    Arzneimittelforschung; 1994 Nov; 44(11):1208-13. PubMed ID: 7848333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.
    Qi M; Jones SB
    Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.
    Bernat A; Herbert JM; Salel V; Lespy L; Maffrand JP
    J Lipid Mediat; 1992 Feb; 5(1):41-8. PubMed ID: 1391738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is platelet activating factor (PAF) a mediator of endotoxin shock?
    Terashita Z; Imura Y; Nishikawa K; Sumida S
    Eur J Pharmacol; 1985 Feb; 109(2):257-61. PubMed ID: 3996473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of platelet-activating factor antagonist SRI 63-441 on endotoxin-induced changes in rat mesenteric microcirculation.
    Li SH; Fei X; Gong XQ; Wu ZL
    Yao Xue Xue Bao; 1991; 26(1):6-9. PubMed ID: 1887797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of endotoxin-induced increase in glucose metabolism by platelet-activating factor antagonist.
    Lang CH; Dobrescu C; Hargrove DM; Bagby GJ; Spitzer JJ
    Circ Shock; 1987; 23(3):179-88. PubMed ID: 3427772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a role of platelet activating factor in hypovolemic shock in the rat.
    Zingarelli B; Squadrito F; Bussolino F; Calapai G; Altavilla D; Ioculano M; Campo GM; Canale P; Caputi AP
    J Lipid Mediat Cell Signal; 1994 Mar; 9(2):123-34. PubMed ID: 8012759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists.
    Wallace JL; Steel G; Whittle BJ; Lagente V; Vargaftig B
    Gastroenterology; 1987 Oct; 93(4):765-73. PubMed ID: 3305134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
    Rabinovici R; Yue TL; Farhat M; Smith EF; Esser KM; Slivjak M; Feuerstein G
    J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Involvement of platelet activating factors in pathologic leukocyte-endothelium interactions in the liver after hemorrhagic shock].
    Marzi I; Bauer M; Reisdorf E; Walcher F
    Zentralbl Chir; 1994; 119(11):814-21. PubMed ID: 7846961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-activating factor and bacteremia-induced pulmonary hypertension.
    Clavijo LC; Carter MB; Matheson PJ; Wills-Frank LA; Wilson MA; Wead WB; Garrison RN
    J Surg Res; 2000 Feb; 88(2):173-80. PubMed ID: 10644485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of in vivo 'priming' on endotoxin-induced hypotension and tissue injury. The role of PAF and tumor necrosis factor.
    Sun XM; Hsueh W; Torre-Amione G
    Am J Pathol; 1990 Apr; 136(4):949-56. PubMed ID: 2327475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
    J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of platelet-activating factor in conscious, normotensive endotoxemia.
    Ephgrave K; Kremer T; Broadhurst K; Cullen J
    J Surg Res; 1997 Mar; 68(2):170-4. PubMed ID: 9184676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of adrenal steroids in the recovery from platelet activating factor challenge.
    Myers AK; Bader TJ
    Circ Shock; 1987; 23(2):143-50. PubMed ID: 3677334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone.
    Feuerstein G; Lux WE; Snyder F; Ezra D; Faden AI
    Circ Shock; 1984; 13(3):255-60. PubMed ID: 6432359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-activating factor antagonists in experimental shock.
    Muacevic G; Heuer HO
    Arzneimittelforschung; 1992 Aug; 42(8):1001-4. PubMed ID: 1418068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of vasoactive mediator antagonists on endotoxic shock in dogs. I.
    Toth PD; Hamburger SA; Judy WV
    Circ Shock; 1984; 12(4):277-86. PubMed ID: 6722995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.